| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 57 | 2021 | 7551 | 4.810 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 16 | 2021 | 361 | 2.730 |
Why?
|
| Adrenal Gland Neoplasms | 12 | 2024 | 489 | 2.550 |
Why?
|
| Contrast Media | 27 | 2019 | 1472 | 2.540 |
Why?
|
| Perfusion Imaging | 8 | 2018 | 30 | 2.120 |
Why?
|
| Neuroendocrine Tumors | 8 | 2019 | 634 | 1.960 |
Why?
|
| Liver Neoplasms | 23 | 2019 | 4557 | 1.820 |
Why?
|
| Liver | 9 | 2018 | 2961 | 1.310 |
Why?
|
| Radiographic Image Enhancement | 8 | 2019 | 402 | 1.180 |
Why?
|
| Image Enhancement | 6 | 2015 | 561 | 1.160 |
Why?
|
| Kidney Neoplasms | 20 | 2018 | 3022 | 1.140 |
Why?
|
| Neovascularization, Pathologic | 7 | 2019 | 1547 | 1.070 |
Why?
|
| Artifacts | 6 | 2018 | 532 | 1.010 |
Why?
|
| Carcinoma, Renal Cell | 18 | 2018 | 2326 | 0.980 |
Why?
|
| Diagnostic Imaging | 6 | 2017 | 1162 | 0.980 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2015 | 7702 | 0.850 |
Why?
|
| Gadolinium DTPA | 4 | 2011 | 172 | 0.820 |
Why?
|
| Aged | 85 | 2021 | 70117 | 0.790 |
Why?
|
| Interferon-alpha | 6 | 2013 | 889 | 0.770 |
Why?
|
| Carcinoid Tumor | 4 | 2015 | 280 | 0.760 |
Why?
|
| Lung Neoplasms | 12 | 2018 | 11538 | 0.760 |
Why?
|
| Reproducibility of Results | 18 | 2018 | 6009 | 0.730 |
Why?
|
| Everolimus | 4 | 2018 | 415 | 0.710 |
Why?
|
| Middle Aged | 92 | 2024 | 86204 | 0.710 |
Why?
|
| Bevacizumab | 9 | 2018 | 938 | 0.690 |
Why?
|
| Abdomen, Acute | 2 | 2010 | 36 | 0.680 |
Why?
|
| Male | 101 | 2021 | 123000 | 0.650 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 70 | 0.650 |
Why?
|
| Triiodobenzoic Acids | 4 | 2012 | 68 | 0.650 |
Why?
|
| Blood Flow Velocity | 8 | 2015 | 475 | 0.640 |
Why?
|
| Sensitivity and Specificity | 17 | 2018 | 4971 | 0.640 |
Why?
|
| Positron-Emission Tomography | 10 | 2017 | 2173 | 0.630 |
Why?
|
| Adult | 73 | 2024 | 77950 | 0.630 |
Why?
|
| Adrenal Gland Diseases | 2 | 2015 | 72 | 0.600 |
Why?
|
| Liver Circulation | 2 | 2015 | 35 | 0.590 |
Why?
|
| Patient Positioning | 2 | 2018 | 195 | 0.590 |
Why?
|
| Female | 98 | 2021 | 141928 | 0.580 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2010 | 962 | 0.560 |
Why?
|
| Colonography, Computed Tomographic | 2 | 2007 | 53 | 0.520 |
Why?
|
| Histoplasmosis | 1 | 2015 | 74 | 0.520 |
Why?
|
| Humans | 126 | 2024 | 261506 | 0.510 |
Why?
|
| Neoplasm Staging | 22 | 2017 | 13658 | 0.490 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2018 | 1248 | 0.490 |
Why?
|
| Neoplasms | 17 | 2021 | 15193 | 0.490 |
Why?
|
| Aorta | 1 | 2018 | 692 | 0.480 |
Why?
|
| Carboplatin | 1 | 2017 | 823 | 0.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2016 | 15862 | 0.460 |
Why?
|
| Acute Kidney Injury | 2 | 2018 | 739 | 0.460 |
Why?
|
| Blood Volume | 4 | 2015 | 100 | 0.460 |
Why?
|
| Candidiasis | 1 | 2015 | 262 | 0.440 |
Why?
|
| Retrospective Studies | 32 | 2024 | 37905 | 0.430 |
Why?
|
| Aged, 80 and over | 33 | 2019 | 29902 | 0.420 |
Why?
|
| Creatinine | 3 | 2010 | 531 | 0.420 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 833 | 0.410 |
Why?
|
| Algorithms | 6 | 2019 | 3890 | 0.410 |
Why?
|
| Hepatic Artery | 6 | 2015 | 240 | 0.410 |
Why?
|
| Liver Function Tests | 1 | 2011 | 173 | 0.400 |
Why?
|
| Diagnosis, Differential | 8 | 2019 | 4744 | 0.390 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 462 | 0.380 |
Why?
|
| Pulmonary Circulation | 1 | 2011 | 131 | 0.380 |
Why?
|
| Ureteral Neoplasms | 2 | 2010 | 228 | 0.380 |
Why?
|
| Adrenalectomy | 4 | 2018 | 188 | 0.370 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 125 | 0.370 |
Why?
|
| Adrenal Cortex Neoplasms | 3 | 2024 | 223 | 0.360 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2018 | 1226 | 0.360 |
Why?
|
| Oxygen Radioisotopes | 1 | 2009 | 6 | 0.350 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 2 | 2020 | 54 | 0.350 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2019 | 1648 | 0.350 |
Why?
|
| Frail Elderly | 3 | 2007 | 118 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 8 | 2020 | 5061 | 0.320 |
Why?
|
| Liver Diseases | 2 | 2011 | 574 | 0.310 |
Why?
|
| Abdominal Cavity | 1 | 2007 | 20 | 0.310 |
Why?
|
| Ovarian Neoplasms | 5 | 2017 | 4638 | 0.310 |
Why?
|
| Antineoplastic Agents | 16 | 2018 | 14289 | 0.310 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2024 | 172 | 0.310 |
Why?
|
| Neoplasm Metastasis | 12 | 2015 | 5112 | 0.300 |
Why?
|
| Iodine | 2 | 2018 | 54 | 0.300 |
Why?
|
| Radiography, Abdominal | 1 | 2008 | 120 | 0.300 |
Why?
|
| Water | 1 | 2009 | 361 | 0.290 |
Why?
|
| Prognosis | 11 | 2017 | 21713 | 0.290 |
Why?
|
| Immunologic Factors | 2 | 2013 | 649 | 0.290 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2009 | 2341 | 0.280 |
Why?
|
| Biomarkers | 2 | 2015 | 5047 | 0.280 |
Why?
|
| Sirolimus | 4 | 2016 | 814 | 0.280 |
Why?
|
| Young Adult | 18 | 2021 | 21445 | 0.280 |
Why?
|
| Indoles | 4 | 2015 | 1009 | 0.270 |
Why?
|
| Radiopharmaceuticals | 4 | 2018 | 1301 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 7 | 2011 | 4367 | 0.260 |
Why?
|
| Polyglutamic Acid | 3 | 2011 | 47 | 0.260 |
Why?
|
| Child Abuse | 2 | 1998 | 193 | 0.260 |
Why?
|
| Paraganglioma | 1 | 2007 | 170 | 0.260 |
Why?
|
| Kidney Diseases | 1 | 2010 | 691 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2021 | 3251 | 0.250 |
Why?
|
| Area Under Curve | 5 | 2015 | 700 | 0.250 |
Why?
|
| Glioma | 2 | 2015 | 1963 | 0.250 |
Why?
|
| Kidney | 2 | 2010 | 2146 | 0.250 |
Why?
|
| Rats, Nude | 2 | 2015 | 32 | 0.240 |
Why?
|
| Melanoma | 9 | 2012 | 5317 | 0.240 |
Why?
|
| Computed Tomography Angiography | 2 | 2016 | 234 | 0.240 |
Why?
|
| Pheochromocytoma | 2 | 2019 | 281 | 0.240 |
Why?
|
| Angiography | 2 | 2015 | 360 | 0.230 |
Why?
|
| Tumor Burden | 4 | 2018 | 1987 | 0.220 |
Why?
|
| Cecal Neoplasms | 1 | 2002 | 7 | 0.220 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2024 | 141 | 0.220 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 4892 | 0.220 |
Why?
|
| Sample Size | 2 | 2015 | 202 | 0.210 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2011 | 716 | 0.210 |
Why?
|
| Disease-Free Survival | 14 | 2017 | 10001 | 0.210 |
Why?
|
| Adrenal Glands | 2 | 2018 | 122 | 0.200 |
Why?
|
| Treatment Outcome | 33 | 2021 | 32848 | 0.200 |
Why?
|
| Prospective Studies | 9 | 2018 | 12873 | 0.200 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2019 | 355 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2019 | 1171 | 0.190 |
Why?
|
| Benzenesulfonates | 3 | 2012 | 195 | 0.190 |
Why?
|
| Retroperitoneal Space | 2 | 2018 | 145 | 0.190 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 249 | 0.190 |
Why?
|
| Pyridines | 4 | 2012 | 1244 | 0.180 |
Why?
|
| Pyrroles | 2 | 2015 | 576 | 0.180 |
Why?
|
| Abdominal Pain | 1 | 2002 | 369 | 0.180 |
Why?
|
| Colorectal Neoplasms | 4 | 2010 | 3578 | 0.180 |
Why?
|
| Observer Variation | 2 | 2018 | 671 | 0.170 |
Why?
|
| Radiography | 4 | 2015 | 1904 | 0.170 |
Why?
|
| Genes, ras | 2 | 2012 | 667 | 0.160 |
Why?
|
| Rib Fractures | 1 | 1998 | 30 | 0.160 |
Why?
|
| Abdomen | 1 | 2020 | 332 | 0.160 |
Why?
|
| Fluorouracil | 6 | 2013 | 1944 | 0.160 |
Why?
|
| Iohexol | 1 | 2018 | 58 | 0.160 |
Why?
|
| Thalidomide | 2 | 2015 | 569 | 0.160 |
Why?
|
| Lifting | 1 | 1997 | 3 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 604 | 0.160 |
Why?
|
| Maximum Tolerated Dose | 8 | 2016 | 1290 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2021 | 351 | 0.160 |
Why?
|
| Abdominal Injuries | 1 | 1998 | 80 | 0.160 |
Why?
|
| Decision Trees | 1 | 2018 | 178 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 4938 | 0.150 |
Why?
|
| Viscera | 1 | 1997 | 81 | 0.150 |
Why?
|
| Paclitaxel | 2 | 2017 | 1996 | 0.150 |
Why?
|
| Skin Neoplasms | 5 | 2012 | 4654 | 0.150 |
Why?
|
| Medical Staff, Hospital | 1 | 1997 | 118 | 0.140 |
Why?
|
| Workflow | 1 | 2018 | 275 | 0.140 |
Why?
|
| Disease Progression | 6 | 2021 | 6682 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 1997 | 130 | 0.140 |
Why?
|
| Laparoscopy | 2 | 2018 | 1225 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 980 | 0.140 |
Why?
|
| Adenoma | 2 | 2019 | 716 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2018 | 289 | 0.140 |
Why?
|
| Rats | 3 | 2015 | 6086 | 0.140 |
Why?
|
| Deoxycytidine | 5 | 2013 | 1353 | 0.140 |
Why?
|
| Myelolipoma | 1 | 2015 | 12 | 0.130 |
Why?
|
| Time Factors | 8 | 2021 | 12926 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 1555 | 0.130 |
Why?
|
| Whole Body Imaging | 1 | 2016 | 114 | 0.130 |
Why?
|
| Permeability | 1 | 2015 | 167 | 0.130 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2015 | 45 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2015 | 10035 | 0.130 |
Why?
|
| Niacinamide | 4 | 2012 | 421 | 0.130 |
Why?
|
| Subtraction Technique | 2 | 2015 | 141 | 0.130 |
Why?
|
| Motion | 2 | 2016 | 193 | 0.130 |
Why?
|
| Pyrimidines | 3 | 2015 | 3518 | 0.130 |
Why?
|
| Diagnostic Errors | 2 | 2010 | 509 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2012 | 5178 | 0.120 |
Why?
|
| Taxoids | 4 | 2012 | 967 | 0.120 |
Why?
|
| Perfusion | 1 | 2015 | 293 | 0.120 |
Why?
|
| Scrotum | 1 | 2014 | 57 | 0.120 |
Why?
|
| Sulfonamides | 2 | 2015 | 1823 | 0.120 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 209 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 4298 | 0.120 |
Why?
|
| Survival Analysis | 7 | 2014 | 9180 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 150 | 0.120 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 1271 | 0.120 |
Why?
|
| Valproic Acid | 1 | 2015 | 263 | 0.120 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10331 | 0.110 |
Why?
|
| Drug Administration Schedule | 8 | 2016 | 3472 | 0.110 |
Why?
|
| Statistics as Topic | 2 | 2015 | 445 | 0.110 |
Why?
|
| Inpatients | 1 | 2018 | 678 | 0.110 |
Why?
|
| Snake Venoms | 1 | 2012 | 9 | 0.110 |
Why?
|
| Linear Models | 2 | 2013 | 1085 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2014 | 362 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 376 | 0.110 |
Why?
|
| Penile Neoplasms | 1 | 2014 | 161 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 573 | 0.110 |
Why?
|
| ROC Curve | 1 | 2015 | 1183 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 592 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 600 | 0.100 |
Why?
|
| Metformin | 1 | 2016 | 378 | 0.100 |
Why?
|
| Portal Vein | 2 | 2004 | 355 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 750 | 0.100 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2010 | 239 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2011 | 370 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2011 | 1756 | 0.100 |
Why?
|
| Decision Making | 2 | 2010 | 1287 | 0.100 |
Why?
|
| Pentetic Acid | 1 | 2011 | 48 | 0.100 |
Why?
|
| Multimodal Imaging | 2 | 2012 | 550 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2010 | 2027 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 4988 | 0.100 |
Why?
|
| Critical Care | 1 | 2017 | 770 | 0.100 |
Why?
|
| Prostatic Neoplasms | 4 | 2010 | 5767 | 0.100 |
Why?
|
| Follow-Up Studies | 10 | 2018 | 14889 | 0.090 |
Why?
|
| Carcinoma | 1 | 2002 | 2578 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2017 | 717 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 528 | 0.090 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2011 | 153 | 0.090 |
Why?
|
| Survival Rate | 7 | 2015 | 12221 | 0.090 |
Why?
|
| Movement | 2 | 2011 | 556 | 0.090 |
Why?
|
| Farnesol | 1 | 2010 | 15 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2011 | 4757 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 2927 | 0.090 |
Why?
|
| Salicylates | 1 | 2010 | 59 | 0.090 |
Why?
|
| Infusions, Intravenous | 5 | 2013 | 1382 | 0.090 |
Why?
|
| Adolescent | 12 | 2018 | 31252 | 0.090 |
Why?
|
| Hexanones | 1 | 2009 | 10 | 0.090 |
Why?
|
| Albumins | 1 | 2011 | 258 | 0.090 |
Why?
|
| Farnesyltranstransferase | 1 | 2009 | 122 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2017 | 945 | 0.090 |
Why?
|
| Gadolinium | 1 | 2010 | 164 | 0.090 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 141 | 0.090 |
Why?
|
| Anilides | 1 | 2011 | 268 | 0.080 |
Why?
|
| Isotope Labeling | 1 | 2009 | 142 | 0.080 |
Why?
|
| Quinolones | 1 | 2009 | 160 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2014 | 1533 | 0.080 |
Why?
|
| Arsenicals | 1 | 2009 | 201 | 0.080 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2021 | 160 | 0.080 |
Why?
|
| Bayes Theorem | 3 | 2019 | 1021 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2012 | 842 | 0.080 |
Why?
|
| Mitotane | 1 | 2007 | 39 | 0.080 |
Why?
|
| Urethral Neoplasms | 1 | 2008 | 60 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 4975 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1664 | 0.080 |
Why?
|
| Curcumin | 1 | 2008 | 117 | 0.080 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 657 | 0.080 |
Why?
|
| Pneumonia | 1 | 2013 | 751 | 0.080 |
Why?
|
| Benzamides | 2 | 2010 | 1832 | 0.080 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 519 | 0.080 |
Why?
|
| Cohort Studies | 7 | 2017 | 9244 | 0.080 |
Why?
|
| Hepatic Veins | 2 | 2004 | 58 | 0.070 |
Why?
|
| Glutathione | 1 | 2009 | 368 | 0.070 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 82 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2007 | 95 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 4078 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2010 | 619 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2011 | 171 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2015 | 1544 | 0.070 |
Why?
|
| Pentostatin | 1 | 2006 | 119 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2014 | 2295 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2018 | 5542 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 133 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2007 | 235 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 2315 | 0.070 |
Why?
|
| Respiration | 1 | 2007 | 447 | 0.060 |
Why?
|
| Eye Diseases | 1 | 2006 | 132 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 627 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2012 | 2330 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 821 | 0.060 |
Why?
|
| Eye | 1 | 2006 | 301 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2010 | 1274 | 0.060 |
Why?
|
| Remission Induction | 4 | 2013 | 3569 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 14551 | 0.060 |
Why?
|
| Neutropenia | 1 | 2008 | 968 | 0.060 |
Why?
|
| Animals | 7 | 2015 | 59536 | 0.060 |
Why?
|
| Organoplatinum Compounds | 3 | 2012 | 702 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 1304 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 297 | 0.060 |
Why?
|
| Hydrolases | 1 | 2004 | 123 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2012 | 3341 | 0.060 |
Why?
|
| Capecitabine | 3 | 2010 | 388 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6207 | 0.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2008 | 4844 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2004 | 121 | 0.050 |
Why?
|
| Phenylurea Compounds | 3 | 2012 | 580 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7226 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2004 | 272 | 0.050 |
Why?
|
| Breast Neoplasms | 4 | 2014 | 15694 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 726 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 840 | 0.050 |
Why?
|
| Thyroid Neoplasms | 2 | 2011 | 1866 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2594 | 0.050 |
Why?
|
| Intestinal Obstruction | 1 | 2004 | 202 | 0.050 |
Why?
|
| Spleen | 1 | 2004 | 676 | 0.050 |
Why?
|
| Indazoles | 2 | 2015 | 297 | 0.050 |
Why?
|
| Endosonography | 1 | 2005 | 536 | 0.050 |
Why?
|
| Length of Stay | 2 | 2010 | 1900 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2003 | 388 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 925 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2012 | 1283 | 0.050 |
Why?
|
| Incidence | 3 | 2018 | 5673 | 0.050 |
Why?
|
| Leucovorin | 2 | 2010 | 332 | 0.040 |
Why?
|
| Ultrasonography | 4 | 2009 | 1863 | 0.040 |
Why?
|
| Lung | 1 | 2011 | 3151 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3981 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 551 | 0.040 |
Why?
|
| Mutation | 4 | 2012 | 15179 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3719 | 0.040 |
Why?
|
| Models, Biological | 1 | 2008 | 3254 | 0.040 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 2576 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1390 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2006 | 1959 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2014 | 756 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2013 | 16273 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 1742 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 665 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5437 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 217 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 1546 | 0.040 |
Why?
|
| Clusterin | 1 | 2017 | 28 | 0.040 |
Why?
|
| Piperazines | 1 | 2007 | 2101 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 7222 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 524 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2017 | 117 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 218 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1429 | 0.040 |
Why?
|
| Needles | 1 | 1997 | 107 | 0.040 |
Why?
|
| Infant | 3 | 2013 | 13310 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2015 | 1529 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2017 | 2316 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1202 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 50 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 85 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 1997 | 145 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 429 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1014 | 0.030 |
Why?
|
| Role | 1 | 2014 | 48 | 0.030 |
Why?
|
| Genital Neoplasms, Male | 1 | 2014 | 44 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2014 | 1529 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2010 | 1869 | 0.030 |
Why?
|
| Smoking | 1 | 2003 | 2440 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 750 | 0.030 |
Why?
|
| Child | 5 | 2018 | 29154 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 2138 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 1299 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2013 | 102 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 272 | 0.030 |
Why?
|
| Glutamates | 1 | 2013 | 130 | 0.030 |
Why?
|
| Patient Selection | 1 | 2021 | 2055 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 151 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 543 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 8865 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 482 | 0.030 |
Why?
|
| Texas | 2 | 2015 | 6311 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 2278 | 0.030 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 615 | 0.030 |
Why?
|
| Quality of Life | 1 | 2006 | 4532 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 54 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2021 | 6869 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 17523 | 0.030 |
Why?
|
| Cisplatin | 2 | 2010 | 2432 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 67 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 219 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 589 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5319 | 0.030 |
Why?
|
| Computational Biology | 1 | 2018 | 1271 | 0.020 |
Why?
|
| United States | 3 | 2018 | 15433 | 0.020 |
Why?
|
| Urography | 1 | 2010 | 43 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 153 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 7548 | 0.020 |
Why?
|
| Primates | 1 | 2011 | 128 | 0.020 |
Why?
|
| Calcification, Physiologic | 1 | 2010 | 56 | 0.020 |
Why?
|
| Kidney Pelvis | 1 | 2010 | 102 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 544 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1363 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2010 | 164 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7789 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2010 | 2054 | 0.020 |
Why?
|
| Dizziness | 1 | 2009 | 47 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 846 | 0.020 |
Why?
|
| Femur | 1 | 2010 | 158 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 754 | 0.020 |
Why?
|
| Polymers | 1 | 2011 | 223 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2006 | 2231 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 231 | 0.020 |
Why?
|
| Urothelium | 1 | 2010 | 254 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4314 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2011 | 717 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 191 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Ataxia | 1 | 2009 | 176 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 435 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2008 | 100 | 0.020 |
Why?
|
| Mice | 4 | 2010 | 34495 | 0.020 |
Why?
|
| Octreotide | 1 | 2008 | 118 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 2010 | 247 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 1391 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 525 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2011 | 710 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 476 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1546 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 437 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 2588 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2007 | 127 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2008 | 485 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 257 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 34 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2007 | 227 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 483 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 114 | 0.020 |
Why?
|
| Gold | 1 | 2007 | 270 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 334 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 2283 | 0.020 |
Why?
|
| Adiposity | 1 | 2007 | 237 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2307 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 329 | 0.020 |
Why?
|
| Critical Illness | 1 | 2010 | 714 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 1506 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 500 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2013 | 1589 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2006 | 264 | 0.020 |
Why?
|
| Pelvic Exenteration | 1 | 2005 | 108 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 987 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2009 | 779 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2010 | 2803 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 255 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 1031 | 0.010 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2004 | 78 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2004 | 200 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 2008 | 493 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 3005 | 0.010 |
Why?
|
| Cholangiocarcinoma | 1 | 2008 | 493 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 698 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2006 | 690 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 866 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2008 | 1549 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 1914 | 0.010 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 1581 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2005 | 962 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2007 | 4307 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 5395 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 2809 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 1415 | 0.010 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 451 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 1819 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 2884 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2003 | 1026 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3890 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 1503 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 4758 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2008 | 2370 | 0.010 |
Why?
|
| Registries | 1 | 2003 | 2170 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 6100 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4849 | 0.010 |
Why?
|